Defining success in treating patients with inflammatory bowel disease

Expert Rev Clin Immunol. 2017 Jul;13(7):645-647. doi: 10.1080/1744666X.2017.1317594. Epub 2017 Apr 17.

Authors

K Theede¹, J Burisch²

Affiliations

¹ a Gastrounit, Medical Division , Copenhagen University Hospital Hvidovre , Hvidovre , Denmark.
² b Department of gastroenterology , North Zealand University Hospital , Frederikssund , Denmark.

PMID: 28395558
DOI: 10.1080/1744666X.2017.1317594

No abstract available

Keywords: Crohn’s disease; disability; mucosal healing; treatment; ulcerative colitis.

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents
Humans
Inflammatory Bowel Diseases / therapy*
Leukocyte L1 Antigen Complex / metabolism
Molecular Targeted Therapy
Patient Satisfaction
Physician-Patient Relations
Quality of Life
Treatment Outcome
Tumor Necrosis Factor-alpha / immunology
Tumor Necrosis Factor-alpha / metabolism*

Substances

Anti-Inflammatory Agents
Leukocyte L1 Antigen Complex
Tumor Necrosis Factor-alpha